Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study
Authors' conclusion
Twelve weeks treatment with exenatide did not lead to a significantly better stent coverage in people with T2D. No significant differences in the occurrence of neo-atherosclerosis were detected between groups.
Study context
- Population
- Subjects with T2D eligible for revascularization with implantation of drug-eluting stent
- Participants
- 38 subjects
- Comparison
- Exenatide once weekly plus standard treatment vs standard treatment alone
- Primary endpoint
- Percentage of strut coverage by optical coherence tomography
- Follow-up
- 12 weeks
Primary result
As reported in the abstract
Strut coverage
P = 0.692
Further findings
Neo-intima thickness · 12 weeks
P = 0.471
Maximal in-stent obstruction by neo-intima · 12 weeks
P = 0.801
- Target lesion revascularization
- P = 0.224
Target lesion revascularization
- No significant differences in rate of target lesion revascularization between groups
Original publication
Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study. Cardiovasc Diabetol. Published 8 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →